Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

By U. Sharma, Saraswati Pokharel, T. van Brakel, Jop H. van Berlo, J. Cleutjens, B. Schroen, S. André, H. Crijns, H. Gabius, J. Maessen and 1 more. Circulation, 2004

924 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Immunology

View Paper: https://www.semanticscholar.org/paper/168179b9f51d965df19a3f1f2d16cd12616c5292

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Ramachandran S. Vasan
2. Daniel Levy
3. Michael J. Pencina
4. Martin G. Larson
5. Véronique L. Roger
6. Jay P. Singh
7. D. Lloyd‐Jones
8. E. Lakatta

Citations in the corpus

• Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community (2012, background): “Galectin-3 (Gal-3) is a beta-galactoside-binding lectin that appears to be a mediator of cardiac fibrosis in a number of recent experimental studies (6,7).”